MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
Express News | Mira Pharmaceuticals Inc - Phase 1 Study Expected to Complete by Q4 2025 - SEC Filing
MIRA Pharmaceuticals | 10-K: FY2024 Annual Report
Express News | Mira Pharmaceuticals Shares Down 3% After All-Stock Deal for Skny Pharma
Mira Pharmaceuticals Signs LOI to Acquire Skny Pharmaceuticals
Express News | Mira Pharmaceuticals Inc - to Acquire Skny Pharmaceuticals - SEC Filing
EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug
Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Strategic Acquisition Expands MIRA's Pipeline With SKNY-1, a Next-generation Oral Therapeutic Targeting the Two Leading Causes of Preventable Death—obesity and Smoking'
Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Signs Binding LOI To Acquire SKNY Pharmaceuticals, Says Securing $5M Capital Infusion To Advance Weight Loss And Smoking Cessation Drug Development
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Express News | Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation
EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate
Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'This Advancement Expands the Company's Pain Management Portfolio Beyond Its Ongoing Ketamir-2 Oral Treatment for Neuropathic Pain'
Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Expands Ketamir-2 Development With Topical Treatment For Localized Neuropathic And Inflammatory Pain
Express News | 'Nevada Senators Take Up Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research' - Marijuana Moment
Express News | Mira Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Tariffs Expected to Bring Pharmaceutical Price Bumps, Shortages -- Market Talk
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Express News | Mira Pharmaceuticals Inc - Submits Ind Application to FDA for Ketamir-2